PHARMA SYMPOSIUM CANADA
Finding the Path to an Accessible and Sustainable Market
Patients with rare diseases have always felt that orphan drugs should be evaluated differently. Now it appears that public payers are coming around to their point of view. READ MORE >>
April 29, 2016
In the past, Patient Support Programs (PSPs) primarily focused on providing patient access; however, changes in the patient journey and within the marketplace have helped to evolve PSPs. The complexity, role and importance of Programs continue to change due in large part to four trends in the Canadian market. READ MORE >>
April 28, 2016
RWD is the foundation of RWE generation, but it is not just a single entity. Rather, RWD is an array of data sources originally generated in most cases for purposes well outside of research. understanding the different types of RWD and their attributes is critical in selecting the most appropriate for research purposes. READ MORE >>
April 26, 2016
In September 2015, PDCI Market Access (PDCI) and H3 Consulting (H3) issued three reports that summarize the findings from a survey of brand drug manufacturers and private payers (insurers and PBMs) focused on Product Listing Agreements (PLAs) in the private insurance market (see Figure 1). Between June 29 and July 17, 2015, 27 individuals responded: 19 manufacturers and 8 private payers. READ MORE >>
April 25, 2016
When: Tuesday, May 3 & Wednesday May 4, 2016
Where: Marriott Bloor Yorkville
To learn more visit: PharmaSymposium
» Should Canada establish a national pharmacare program?
» What will be the result of the Patented Medicine Prices Review Board
(PMPRB) strategic review? Will its mandate change?
» How will the Institut national d’excellence en santé et services sociaux
(INESSS) move forward now that Québec has joined the pCPA?
» Can the path to market be streamlined so that Canadians can benefit
from new therapies sooner and Canada is viewed more seriously as a
place to invest?
» Will the path to market for biosimilars gain greater clarity in 2016?